NTERLEUKIN-3 (L-3) stimulates the production of mature cells of multiple hematopoietic lineages, including granulocytes, monocytes, red blood cells, and thrombocytes. It acts on immature, multipotent hematopoietic cells as well as on more differentiated progenitor cells restricted to individual lineages, in particular to those of basophilic and eosinophilic granulocyte^."^ IL-3 also stimulates the proliferation of normal and leukemic B cells, which may imply that certain stages of B-lymphocyte development are influenced as Multilineage stimulation has been documented after IL-3 administration to humans and nonhuman primates, indicating that L -3 alone, or in combination with other cytokines, may be useful as a therapeutic agent to accelerate or restore hematopoietic in myelosuppressed patients. [12] [13] [14] [15] [16] The IL-3 receptor (L-3R) consists of an a-chain that can bind IL-3 with low affinity and a &chain that does not bind IL-3 by itself but is necessary for formation of a high-affinity receptor complex and signal transd~ction.'~-'~ In humans, the P-chain is also an essential component of the high-affinity receptors for IL-5 and granulocyte-macrophage colony-stimdating factor (GM-CSF).20,2' Low-level IL-3R expression has been identified on various leukemic cell lines, blast cells of some patients with acute myeloid leukemia (AML), normal human peripheral blood (PB) monocytes, basophils of chronic myeloid leukemia patients, and eosinophils of patients with h y p e r e o s i n~p h i l i a .~~~~~ Using radiolabeled ligand, IL-3Rs have been detected on unfractionated bone marrow (BM) cells as well as on purified CD34+ cells, but the average level of expression appeared to be very low, ie, -50 molecules per cell.30s3' Using specific monoclonal antibodies (MoAbs), the IL-3R a-chain and the common P-chain have been identified on CD34+ cells and on cells expressing myeloid or B-lymphoid antigens, which is consistent with the activities of IL-3 in myelopoiesis as well as B lymphopoie- DRd"" cells, with the latter population expression approximately twofold to threefold lower IL-3R levels. A large fraction (>309'0) of single-cell/well-sorted CD34b"aM/RhlA-DRd"" cells formed multilineage colonies after 2 to 4 weeks of stimulation with IL-3, GM-CSF, Kit ligand, and IL-6. Individual colonies contained cells that still expressed CD34 as well as differentiated monocytes, granulocytes, and erythroid cells. These results confirmed that the CD34hbM/RhLA-DRd"" subset was enriched for immature, multipotent progenitor cells, whereas the CD34h'gM/RhLA-DR"gM population mainly contained lineage-committed precursors. The results are consistent with the concept that IL-3Rs are induced at very early stages of hematopoiesis, as identified by high expression of CD34 and low expression of RhLA-DR. IL-3R expression continues to be low during differentiation into lineage-committed progenitors; gradually increases on differentiating progenitor cells for B cells, granulocytes, monocytes, and, possibly also, erythrocytes; but finally declines to undetectable levels during terminal differentiation into mature cells of all lineages in peripheral blood, with the exception of basophils. These data show that differential IL-3R expression is a useful parameter to isolate specific progenitor cells subsets or to deplete IL-3R' cells from the CD34b"gM population to isolate the most immature stem cell candidates. 0 7995 by The American Society of Hematology.
However, the precise stage of differentiation and the functional capacities of BM cells that express IL-~Rs, particularly within the immature CD34+ subset, have not been firmly established, whereas changes in IL-3R expression as a result of lineage commitment and differentiation have not been investigated either. CD34+ cells are heterogeneous in phenotype, differentiation stage, and developmental capacity and consist of very immature cells that sustain long-term multilineage hemopoiesis in vitro and in vivo, as well as more differentiation progenitor cells with more restricted proliferation and differentiation capacity. Phenotypically, subsets of CD34-expressing cells can be distinguished on the basis of relative levels of specific cell-surface antigens associated with activation status, eg, HLA-DR, or with lineage commitment and differentiation, eg, CD10 and CD19 for B lymphoid cells, CD71 for erythroid cells, and CD33 and CD1 Ib for monocytes and granulocyte^.^^"^
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W O G N U M ET A1
In previous studies, we have established that receptors for IL-6 and GM-CSF are expressed on subsets of CD34+ cells in BM of humans and rhesus monkeys as well as on mature monocytes and neutrophils and the immediate precursors of these In those studies, receptor distribution was examined by flow cytometry after staining of BM cells with biologically active preparations of the respective biotin-labeled ligands in combination with fluorescently tagged streptavidin. This method enabled us to identify and characterize small subsets of receptor-expressing cells as well as to isolate hematopoietic cell subsets on the basis of their receptor phenotype for subsequent analysis of growth and differentiation capacities in culture. In the present study, we have used the same flow cytometric approach to obtain a detailed analysis of IL-3R expression on defined subsets of immature hematopoietic cells of BM in normal rhesus monkeys.
MATERIALS AND METHODS
ZL-3.
Recombinant rhesus monkey IL-3, expressed in Bacillus lichenifonnis, was purified to homogeneity as d e~c r i b e d .~"~ Biotinylation was performed essentially as previously described for L -6 and GM-CSF with modifi~ations.4~~~' Briefly, 70 kg of L -3 in 0.1 mol/L sodium bicarbonate buffer, pH 8.4, containing 0.02% (wt/ vol) Tween-20, was incubated with a 10-fold molar excess of Nhydroxy-succinymidyl-biotin (Sigma, St Louis, MO) for 2 hours at 20°C, after which biotin-labeled IL-3 was separated from unbound reagent by size exclusion chromatography on a 1 mL Sephadex G-25 column (Pharmacia, Uppsala, Sweden) equilibrated in phosphatebuffered saline containing 0.02% (weightkol) Tween-20. IL-3 bioactivity was tested in a 'H-thymidine uptake assay using M07E cells.& Only batches of which greater than 99% of biologically active IL-3 was biotin labeled, as tested by absorption to streptavidinagarose beads (Sigma), were used.
Antibodies. Mouse MoAbs against human cell-surface markers were used that can react with the corresponding rhesus monkey proteins. R-phycoerythrin (RPE)-conjugated antibodies against CD4, CD8, CD1 Ib, CD20, CD71, and HLA-DR as well as peridinin chlorophyll protein (PerCP)-conjugated anti-HLA-DR were purchased from Becton Dickinson (San Jose, CA). Anti-CD34 MoAbs 561 and 566 were developed by Egeland and Gaudernack." Anti-CD34 #566 was labeled with fluorescein isothiocyanate (FITC) according to standard procedures. Nonconjugated anti-CD10 antibody J5 and anti-CD27 antibody 9F448 were kindly provided by Dr J. Ritz (Dana Farber Cancer Institute, Boston, MA) and Dr W. Loenen (Netherlands Cancer Institute, Amsterdam, The Netherlands), respectively. FITC-conjugated goat antimouse Ig (GAM-FITC) and rabbit antihuman IgM antibodies were purchased from DAKO (Glostrup, Denmark).
Procurement of BM and PB cells. PB was obtained by vena puncture. BM was collected from young adult rhesus monkeys (Macaca rnulatta) bred at the TNO Primate Center (Rijswijk, The Netherlands) by piercing the head of the humeral shaft with a pediatric spinal needle (Terumo, Tokyo, Japan) to obtain small samples or by piercing the knee joint into the femoral shaft in case larger amounts of BM were needed.I3 To enrich for progenitor cells, buffy coat cells were subjected to a discontinuous bovine serum albumin (BSA)-density gradient to isolate low-density ~e l l s . 4~ Residual red blood cells were removed by osmotic lysis using IO mmoVL potassium bicarbonate, 155 mmoVL ammonium chloride, pH 7.4, containing 0.1 mmoVL EDTA.
PuriJication of CD34' cells. Starting from low-density BM cells, CD34+ cells were purified using an IgG2A antibody against CD34 (MoAb 561) that was noncovalently linked to rat-antimouse IgG2a-conjugated immunomagnetic beads (Dynabeads; Dynal, Oslo, Norway)?' CD34+ cells were eluted from the beads using a polyclonal antibody preparation directed against the Fab part of the anti-CD34 antibody (Detachabead; Dynal)." The eluted cell population was devoid of antLCD34 antibodies and was greater than 60% to 95% CD34' as determined by FACS analysis after restaining with FITCanti-CD34. Recovery of CD34' cells ranged between 37% and 45% of CD34' cells in the low-density fraction (4 experiments).
Binding of biotin-labeled ZL-3 to cells. Cells (final concentration, 1 X 107/mL) were incubated with biotin-labeled IL-3 (at a concentration of 4 nmo1L) in HEPES-buffered Hank's balanced salt solution, containing 2% (voVvol) of fetal bovine serum and 0.05% (weight/ vol) of sodium azide (HFN) for 15 hours on ice. Nonspecific binding of biotin-IL-3 was evaluated in the presence of a 100-to 200-fold molar excess of nonlabeled IL-3. After incubation, cells were washed twice and incubated with streptavidin-phycoerythrin (SA-RPE; Molecular Probes, Eugene, OR) at a concentration of 7 pg/mL for l hour on ice. The fluorescence intensity was then amplified by sequential incubation with a biotin-labeled anti-RPE MoAb and a second incubation with SA-RPE, as described." For two-color analysis, cells were stained during the last SA-RPE incubation step with FITCanti-CD34, FITC-anti-IgM, or HTC-anti-CD20. For three-color analysis, samples of cells were simultaneously incubated with SA-RPE, FITC-anti-CD34, and PerCP-conjugated anti-HLA-DR. Controls included cells stained with the respective fluorescent antibodies separately. Antibody incubations were performed in the presence of 2% (vol/vol) normal rhesus monkey serum or 2% normal rabbit serum (for detection of IgM expression) to prevent nonspecific antibody binding. Normal goat serum (2%) was included in secondary incubations with GAM-FITC.
Phenotypic analysis. Selected populations of sorted and unsorted cells were examined in parallel three-color flow cytometry experiments using RPE-conjugated antibodies against CD4, CD8, CD20. and CDllb, together with FITC-anti-CD34 and PerCP-labeled anti-HLA-DR. To identify pre-B cells, immunomagnetically purified CD34+ cells were stained with unconjugated anti-CD10 and anti-CD27, respectively, followed by staining with GAM-FITC.
Flow cytometry and cell sorting. Analytical two-and three-color experiments were performed using a FACScan flow cytometer (Becton Dickinson). Spillover of FITC fluorescence in the RPE and PerCP detectors and of RPE in the PerCP detector was electronically compensated using appropriately stained control cells. List mode data for 10,000 to 50,000 cells were collected either ungated or in an electronic gate for cells with intermediate-to-high forward light scatter and low-to-intermediate right angle light scatter to exclude dead cells and mature granulocytes from the analysis. List mode data for 1,000 to 2,000 events were collected in a gate for CD34' cells to analyze IL-3R and RhLA-DR expression on the CD34' subset. Flow cytometric data were analyzed using Lysys I1 software (Becton Dickinson). Two-color cell sorting experiments were performed using a FACS Vantage flow cytometer (Becton Dickinson) with the Argon laser at 488 nm (100 mW). Purity of sorted populations as verified by reanalysis was greater than 98%. For clonal analysis, individual cells were directly sorted into separate wells of 96-well culture plates (Becton Dickinson) containing culture medium using the automated single-cell deposit unit of the FACS Vantage. Accuracy of each single-cell sort was verified by sorting single FITC-labeled latex microspheres (Polysciences, Warrington, PA) onto microscope slides and inspecting the slides using a fluorescence microscope.
Clonogenic assay of sorted cells. Cells were plated in 35-mm dishes (Becton Dickinson) in 1 mL a-minimal essential medium (a-MEM; GIBCO, Gaithersburg, MD) containing 0.8% methylcellulose, 5% fetal calf serum (FCS), 1% BSA, glutamine (2 rnmoVL), insulin (10 mg/mL), linoleic acid and cholesterol (1.5 X mol/ L), sodium selenite (1 X IO" mom), nucleosides (each at I mg/ mL), 2-mercapto-ethanol ( l X mom), iron-saturated human
For personal use only. on October 31, 2017. by guest www.bloodjournal.org 
anti-CD3bFlTC
transfemn (0.6 mg/mL), penicillin (100 U/mL), and streptomycin (50 pg/mL). For burst-forming units-erythroid (BFU-E), cultures were supplemented with hemin (2 X mol/L), human recombinant erythropoietin (Epo; 4 UlmL; Behring, Germany), and Kit ligand (U; 100 ng/mL; kindly provided by Dr S. Gillis. Immunex, Seattle, WA). For colony-forming units-culture (CFU-C), cultures were supplemented with recombinant human GM-CSF (5 ng/mL; Behring), recombinant rhesus monkey L 3 (30 ng/mL), and KL. Unsorted cells were plated at 5 X IO4 cells per dish and sorted cells were plated at concentrations ranging between 10' and 5 X IO3 per dish. Colonies were counted at day 12. CFU-C included CFU-GM, CFU-G, and CFU-M. Colony numbers represent the mean 2 standard error of duplicate dishes, assuming that colony counts are Poisson distributed."
Liquid suspension cultures. To measure short-term growth, 1,000 to 2,000 BM cells sorted on the basis of CD34 and IL-3R expression were cultured in medium alone or with GM-CSF (5 ngl mL), IL-3 (30 ng/mL), or L 3 plus GM-CSF in wells of 96-well tissue culture plates. Cells were expanded by transfer to 1 mL wells in 24-well culture plates (Costar, Cambridge, MA) after 4 days. After 10 days, cells were harvested and phenotypic and morphologic analysis was performed. Clonal cultures of individually sorted CD34h"gh'/RhLA-DRh"gh' and CD34""gh'/RhLA-DRd"'' cells were stimulated with IL-3, GM-CSF, and KL with or without IL-6 (IO nglmL; Ares-Serono, Geneva, Switzerland) and expanded before reaching confluency (usually between 7 and 21 days of culture). After expansion, cells were counted, 10% were replated into secondary 1 mL cultures, 10% were used for morphologic analysis after Forward light scatter cytocentrifugation, and the remaining cells were used for phenotypic analysis by flow cytometry. For flow cytometric analysis, parallel samples were incubated with FITC-anti-CD34 and RPE-anti-HLA-DR. FITC-anti-CD71 and RPE-anti-CDI Ib, or FITC-anti-CD2 and RPE-anti-CD20 to identify clones that contain immature cells (CD34'). erythroid cells (CD7IMRh'/CDI 1 b-RILA-DR-), granulocytes (CD7I1""/CDI 1 b+/HLA-DR-), monocytes (CD7 1 '""/ CD1 I b+/HLA-DR'), or that consisted of mixed populations.
RESULTS
IL-3R expression on low-density cells.
To assess the distribution of IL-3Rs on hematopoietic cells, BM cells of healthy rhesus monkeys were analyzed by flow cytometry after staining with biotinylated IL-3 and phycoerythrin-conjugated streptavidin and counterstaining with FITC-anti-CD34. IL-3Rs were identified in unfractionated BM, but only at low frequencies (2% to 5% in 4 experiments; data not shown). In the low-density BM fraction, several distinct populations of CD34-, CD34dU", and CD34bneh' cells stained specifically with the biotinylated IL-3 (Fig 1A) as compared with controls (cells stained with biotinylated IL-3 in the presence of excess unlabeled IL-3; Fig 1B) . Expression on CD34-cells was low and these cells displayed very low forward light scatter, which is characteristic for lymphoid cells (Fig 1C; see below) .
A minor fraction of CD34dU" cells stained intensely with
For Fig 1A) . These cells resembled immature blast-like cells as judged by intermediate-to-high forward light scatter (Fig 1C) as well as morphology of sorted cells (Fig 2A) . The CD34dU"/IL-3Rbrigh' cells did not form colonies in standard clonogenic assays in semisolid culture medium (data not shown) but developed into small compact clusters of myeloblast-like cells in liquid suspension culture with IL-3 and/or GM-CSF (Fig 2B and C) . These clusters appeared after 3 days and increased slowly in size up to -100 cells per cluster until day 10, after which the cells died. More mature cells resembling monocytes, basophils, and neutrophils were also identified (Fig 2B and D) . Hence, IL-3Rs are expressed at high levels on precursor cells for granulocyte/macrophage lineages. A second subset of CD34d"" cells also expressed IL-~Rs, but at lower levels ( Fig  1A) . These CD34d""/IL-3Rd"" cells contained lymphocytelike cells with low forward light scatter as well as larger blast-like cells (Fig 1C) .
IL-3R expression on CD34b"gh' cells was lower than on the other subsets (Fig 1) . Cell sorting experiments were performed to examine whether CD34b"ght/IL-3RdU" cells were functionally distinct from the CD34'ngh'/IL-3R-cells. Both populations were indistinguishable with respect to forward light scatter (Fig IC) and morphology (Fig 2D and F) and consisted of large, immature blast-like cells and smaller cells with undifferentiated morphology (Fig 2D and F) . However, both subsets were functionally different, as few CD34'nght/ IL-3Rdu" cells formed colonies (Table 1) . Most colony-forming cells were present in the CD34h"ght/IL-3R-population, which was enriched twofold to threefold for BFU-E and CFU-C relative to total CD34b"gh' cells ( Table 1) .
The growth factor responses of the sorted cells were also tested in liquid suspension cultures. IL-3 stimulated the proliferation of CD34'nght/IL-3R-cells in the absence of other cytokines and augmented the response to KL, GM-CSF + KL, IL-6, and Epo. Maximal expansion (800-fold) was achieved with the combination of IL-3 + KL + Epo after 14 days of culture (Table 2 ). This ability of the CD34'ngh'/ IL-3R-cells to respond to IL-3 indicated that these cells do express some IL-3Rs at levels below the detection limit or start to express IL-3Rs during culture.
The CD34b"gh'/IL-3Rd"" cells produced fewer progeny than the CD34b"ght/IL-3R-cells with most growth factor stimuli (Table 2) . Only with IL-3 plus either KL + GM-CSF or KL + Epo was proliferation of the CD34bnght/IL-3RdU" cells similar to that of the CD34b"ght/IL-3R-cells (Table 2) . However, most cultured CD34bngh'/IL-3Rd"" cells had lost CD34 expression, whereas a much larger proportion of the CD34'ngh'/IL-3R-cells still expressed CD34 after 14 days of culture (Table 2 ) and continued to grow beyond 14 days of culture (data not shown). Cells produced after 14 days of culture of CD34h"gh'/IL-3Rd"" cells included differentiating neutrophils, monocytes, and erythroblasts (Fig 2E) , which indicated that precursors of these lineages can be separated from less differentiated progenitor cells on the basis of higher IL-3R expression levels.
IL-3R expression on immature hematopoietic cells. The nature of the IL-3R+ cells was further investigated by comparison with CD34 and RhLA-DR expression on low-density BM cells and on purified CD34+ cells using three-color flow cytometry (Fig 3) . This method allows for a better resolution of IL-3R+ subsets than the sorting experiments described above. The relation between CD34 and RhLA-DR expression is presented in the top panels of Fig 3. The histograms in the lower part of Fig 3 show IL-3R expression in each of 6 distinct regions identified on the basis of CD34 and RhLA-DR expression. IL-3R+ CD34'ngh' cells were detectable in the RhLA-DRhnSh' subset (region 1) and in the smaller RhLADRd"" subset (region 2), which was even more clear on purified CD34' cells (Fig 3B) . IL-3R levels on the CD34bngh'/ RhLA-DRd"" cells were twofold to threefold lower than on CD34b"gh'/HLA-DRhngh' human BM cells have been shown to represent lineage-committed and differentiating cells, whereas the CD34h"ghtMLA-DRdU" cells represent multilineage cells that can initiate and sustain hematopoietic in longterm BM c u l t~r e s .~~~'~~~~ The finding that the rhesus monkey CD34h"ght/RhLA-DRd"" subsets also express IL-3Rs suggested that IL-3Rs are present on very early cells. Singlecell sorting experiments were performed to establish the presence of multipotent cells within the CD34'ngh'/RhLADRd"" population and to determine the responsiveness of these cells to IL-3. As shown in Table 3 , approximately 50% of sorted CD34'nght/RhLA-DRhngh' and CD34'ngh'/RhLADRd"" cells proliferated in these clonal cultures after stimulation with IL-3, GM-CSF, and KL. A higher cloning efficiency (60% to 70%) was achieved when IL-6 was included in the culture medium (Table 3) . With all four growth factors, more than 50% of the proliferating CD34'nght/RhLA-DRd"" cells (ie, -30% of sorted cells) expanded to large clones. The majority of these large clones (26 of 31 in cultures with IL-3, GM-CSF, KL, and IL-6) contained two lineages (granulocytes and monocytes) or three lineages (granulocytes, monocytes, and erythroid cells) as well as large numbers of CD34+ cells (Table 3) . Some of the large clones, particularly those with mixed phenotype, continued to expand for another 1 to 3 weeks after replating in secondary cultures and reached cell numbers that ranged between 5 X IO5 and 17 X lo6 cells (median, 8.5 X lo6) per clone, showing the high proliferative potential and replating potential of these cells (Table 3) .
Most clones derived from CD34hr'gh'/RhLA-DRh"gh' cells did not survive beyond 2 to 3 weeks of culture and did not contain enough cells for phenotypic analysis. Most of the few cells that did expand to large clones (> lo4 cells) contained only a single lineage, ie, granulocytes or erythroid cells (Table 3 ). This finding indicated that most CD34h"Sh'/ RhLA-DRhngh' cells had only a limited proliferation and differentiation potential.
The high plating efficiency of CD34b"gh'/RhLA-DRd"" cells made it possible to evaluate the cytokine responsiveness of these cells in greater detail. These cells did not expand to large clones when grown in medium only or in the presence of each cytokine individually (data not shown), but suboptimal outgrowth was achieved with two-and three-factor combinations (Table 3) . IL-3 augmented the cloning efficiency of large clones stimulated by IL-6 + KL and, particularly, IL-6 + KL + GM-CSF (Table 3) . These results showed that IL-3 can stimulate the outgrowth of multipotent hematopoietic rhesus monkey BM cells at the single-cell level in conjunction with other growth factors. 
IL-3R expression on B-lymphocyte precursors.
The comparison with CD34 and RhLA-DR expression also allowed for the further characterization of more differentiated cells that expressed the IL-3R (Fig 3, regions 3 to 6 ). IL-3R expression patterns on CD34d""/RhLA-DRb"ph' cells (region 3 in Fig 3) in the low-density BM fraction (Fig 3A) as well as on purified CD34+ cells ( Fig 3B) were virtually identical. Most CD34du1'/RhLA-DRb"gh' cells were L-3Rd"" (average fluorescence intensity, 10' to 10'). Approximately 50% to 60% of these cells consisted of large blast cells; the others were characterized by low forward light scatter, similar to the CD34-/IL-3RdU" cells identified in Fig 1. Although analysis of CD19 expression was not possible because of lack of an antibody that cross-reacted with rhesus monkey CD19, most small CD34d"'L/RhLA-DRbngb' cells expressed two markers associated with B-cell development, ie, CD10 and CD27,53 but not the late B-cell antigen CD20 or the T-cell antigen CD2. The results indicated that this subset of IL-3R' cells consisted of B-lymphocyte precursors (data not shown). The less frequent CD34du1'mhLA-DRb"gh' cells that expressed L-3R at high levels (average fluorescence intensity, -lo3) were identical to the CD34d"'1/IL-3Rb"gh' monocyte and granulocyte precursors previously identified in twocolor cell sorting experiments (Fig 2A through C) . The CD34-BM cells that expressed IL-3Rs were only detected in the CD34-/RhLA-DRbngh' subset (region 5 in Fig  3A) . Results of parallel three-color experiments (data not shown) indicated that the CD34"ILA-DRbngh' population (region 5 in Fig 3A) contained CDllb+ monocytes and CD20' B lymphocytes. To examine whether the IL-3Rdu"/ CD34-/RhLA-DRbnght cells represented B lymphocytes, IL-3R expression was compared with expression of two markers that appear late during B-cell differentiation, ie, CD20 and surface IgM.33 As shown in Fig 4, L-3Rs were not detected on CD2Obngh' rhesus monkey cells, ruling out the possibility that the L-3R-expressing cells were mature B lymphocytes (Fig 4D) . However, IL-3Rs were detected on many cells (38% and 25% in 2 separate samples) with low CD20 levels ( Fig 4C) and also on a smaller fraction (17% and 23%) of surface IgM' cells (Fig 4F) . Surface IgM was present on CD20d"" and CD20bngh' cells (Fig 4A) , which indicated that the IL-3R'/CD2Odua cells and IL-3R'/sIgM+ cells were identical. Because CD20 reaches its maximal expression on maturing B lymphocytes and CD20dU" cells were not detected in PB (data not shown), the IL-3Rd""/CD34~/RhLA-DRbnght/ CD20d""/surface IgM' BM cells represent immature B cells. 1L-3R expression on these immature B cells was lower than on the IL-3R-expressing CD34d""/RhLA-DRb"gh' pre-B cells identified in region 3 (Fig 3A) , which indicated that IL-3R expression gradually declines during B-cell differentiation. IL-3Rs could not be identified on CD4' and CD8' T lymphocytes, as well as CDllb+ granulocytes and CD71"gh' erythroblasts, that were contained in the CD34d""/RhLA-DR-and CD34-RhLA-DR-subsets (regions 4 and 6 in Fig  3A) . rhesus monkeys. The results of flow cytometric studies with biotinylated IL-3 showed that IL-3Rs are expressed on a relatively small number (-2% to 5%) of nucleated BM cells. The results also show that IL3R levels on BM cells are highly variable, with 10-to 100-fold differences in expression between IL-3R""" and IL-3Rbngh' cells.
Our data are consistent with the concept that IL-3Rs are induced at very early stages of hematopoiesis. IL3R expression continues to be low during differentiation into lineagecommitted progenitors; gradually increases on precursors for B cells, granulocytes, monocytes, and erythrocytes; but finally declines to undetectable levels during terminal differentiation into mature PB cells.
IL3R expression is most prominent during myeloid differentiation. This expression was shown by the increased IL-3R expression with decreasing CD34 expression and by the production of monocytes and granulocytes in cultures of sorted CD34h"gh'/IL-3Rd"" and CD34d""/IL-3Rb"gh1 cells. The gradual increase of IL-3R expression parallels the expression of IL-6R and GM-CSFR expression during monocyte and granulocyte differentiation, which is consistent with the similar hematopoietic activities of these cytokines in vitro and in vivo. However, IL-6Rs and GM-CSFRs continue to be expressed on mature monocytes and neutrophil^.^^.^^ In contrast, IL-3Rs are neither detectable on mature monocytes and neutrophils. The absence of IL-3Rs on mature neutrophils is consistent with the results of radiolabeled IL-3 binding studies on human and rhesus monkey cells,".." but the absence of detectable IL3R expression on rhesus monkey monocytes contrasts with the reported presence of IL-3Rs on partially purified human monocyte^.^^^^^^^^.^^ This finding may indicate that IL-3R levels on rhesus monkey monocytes are below the detection limit of the flow cytometric method or that interspecies differences exist with respect to IL-3R distribution. The latter explanation is conceivable in view of the unusually fast divergence of IL-3 during evolution that may also have resulted in functional alterations." Alternatively, the purification methods used for human monocytes did not preclude contamination with basophils, which express IL3Rs at 2-to 20-fold higher levels than monocytes.24'~R~30 Such contamination is less likely to occur for rhesus monkey monocytes, because basophilic granulocytes are virtually undetectable in PB of normal rhesus monkeys. 3' In a parallel study on BM and PB cells of rhesus monkeys treated with recombinant IL-3, we have identified high levels of the IL-3R on basophils that are produced in large quantities in response to in vivo IL-3 treatment.s4' These basophils were found to produce large amount of histamine and are probably associated with the acute nonhematopoietic effects of in vivo IL-3 treatment." The production of basophils in short-term cultures of sorted CD34d""/IL-3Rh"eh' cells in normal monkeys (Fig 2) is consistent with ability of IL-3 to For personal use only. on October 31, 2017. by guest www.bloodjournal.org From IL-3 RECEPTORS DURING IL-3 TREATMENT 589 stimulate basophil production in vivo. Because IL-3 also stimulates the production of other lineages, in particular eosinophils, platelets, and osteoclasts in vivo, it is expected that cells belonging to these lineages can also be selected by high IL-3R expression. The absence of these lineages in cultures of IL-3R' cells in this study may be attributed to the low frequencies of precursors of megakaryocytes, eosinophils, and osteoclasts in normal BM and to the requirement of additional cytokines, in particular IL-6, M-CSF, IL-5, and thrombopoietin, for optimal growth in ~itro.'~-'~ The presence of IL-3Rs on CD34dU"/CD10+/CD20-B-cell precursors and CD34-/CD20d""/surface IgM+ immature B cells is consistent with the reported expression of IL-3Rs on CD19+ human cord blood B cells and human leukemic pre-B-cell lines and also with the ability of IL-3 to stimulate early stages of B-cell differentiati~n.~'"~~~ The lower IL-3R levels on CD34-cells as compared with CD34dU" immature B cells and the absence of IL-3Rs on CD2Ob"8" mature B cells indicate that IL-3Rs gradually decline during terminal B-cell differentiation.
Evidence for the expression of IL-3Rs on immature cells was provided by the detection of IL-3Rs on CD34bnght/RhLADRdu" BM cells, which are enriched for immature multipotent cells with high proliferative capacity in clonal cultures of singlekell well sorted cells. Because not all CD34bnght/ RhLA-DRd"" BM cells were stained specifically with the biotinylated IL-3 (Fig 3B) , we cannot exclude that part of these cells do not express IL-3Rs. However, the ability of IL-3 to stimulate the outgrowth of individual CD34b"ght/RhLADRd"" cells, in conjunction with other cytokines, makes it more likely that IL-3Rs are already expressed on these cells or are rapidly induced after stimulation by other cytokines. Low levels of the IL-3R may go undetected because the flow cytometric method has an estimated detection limit of -50 receptor molecules per ce11.42*43, 51 In previous flow cytometric studies with biotinylated GM-CSF and IL-6, we also identified receptors for these cytokines on CD34+ cells, including the most immature, CD34'/ RhLA-DRd"" s~b s e t . 4 '~~~ The receptor for KL has also been identified on immature, CD34b"ghtMLA-DRdU" cells. 38 These results show that receptors for multiple cytokines are expressed on the same subsets of immature hematopoietic cells, but it is unknown if these receptors are coexpressed on the same cell. Although it has been shown that L 6 may upregulate IL-3R expression and that IL-3 may upregulate GMCSFRs and Epo receptors on purified CD34+ cells,60 it is unknown whether such growth factor effects on the expression of receptors for other cytokines occur on the most immature, eg, CD34b"ght/RhLA-DRd"", stem cell candidates. The flow cytometric method presented here for the IL-3R provides a tool to study these mechanisms related to the possible synergistic or antagonistic actions of different hematopoietic growth factors at the level of single immature hematopoietic cells. The same approach will also allow transplantation of immature CD34+ cells selected on the basis of their receptor phenotype to study their capacity to reconstitute hematopoiesis.
